These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 36413609)
1. A word of caution: Early failure of Magmaris® bioresorbable stent after pulmonary artery stenting. Haddad RN; Adel Hassan A; Al Soufi M; Kasem M Catheter Cardiovasc Interv; 2023 Jan; 101(1):131-134. PubMed ID: 36413609 [TBL] [Abstract][Full Text] [Related]
2. The bioresorbable magnesium scaffold (Magmaris)-State of the art: From basic concept to clinical application. Rola P; Włodarczak S; Doroszko A; Lesiak M; Włodarczak A Catheter Cardiovasc Interv; 2022 Nov; 100(6):1051-1058. PubMed ID: 36229949 [TBL] [Abstract][Full Text] [Related]
3. Effect of non-compliant balloon postdilatation on magnesium-based bioresorbable vascular scaffolds. Blachutzik F; Achenbach S; Tröbs M; Marwan M; Weissner M; Nef H; Schlundt C Catheter Cardiovasc Interv; 2019 Feb; 93(2):202-207. PubMed ID: 30196573 [TBL] [Abstract][Full Text] [Related]
4. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent. Barkholt TØ; Webber B; Holm NR; Ormiston JA Catheter Cardiovasc Interv; 2020 Dec; 96(7):E674-E682. PubMed ID: 31710149 [TBL] [Abstract][Full Text] [Related]
5. First use and limitations of Magmaris® bioresorbable stenting in a low birth weight infant with native aortic coarctation. Sallmon H; Berger F; Cho MY; Opgen-Rhein B Catheter Cardiovasc Interv; 2019 Jun; 93(7):1340-1343. PubMed ID: 31001884 [TBL] [Abstract][Full Text] [Related]
6. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold. Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171 [TBL] [Abstract][Full Text] [Related]
7. In vitro performance investigation of bioresorbable scaffolds - Standard tests for vascular stents and beyond. Schmidt W; Behrens P; Brandt-Wunderlich C; Siewert S; Grabow N; Schmitz KP Cardiovasc Revasc Med; 2016 Sep; 17(6):375-83. PubMed ID: 27266902 [TBL] [Abstract][Full Text] [Related]
12. SICI-GISE Position Document on the Use of the Magmaris Resorbable Magnesium Scaffold in Clinical Practice. Galli S; Testa L; Montorsi P; Bedogni F; Pisano F; Palloshi A; Mauro C; Contarini M; Varbella F; Esposito G; Caramanno G; Secco GG; D'Amico G; Musumeci G; Tarantini G Cardiovasc Revasc Med; 2022 Jan; 34():11-16. PubMed ID: 33674219 [TBL] [Abstract][Full Text] [Related]
13. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry. Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203 [TBL] [Abstract][Full Text] [Related]
14. Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents. Rola P; Włodarczak A; Barycki M; Szudrowicz M; Łanocha M; Kulczycki JJ; Turkiewicz K; Woźnica K; Lesiak M; Doroszko A J Diabetes Res; 2021; 2021():8636050. PubMed ID: 34859105 [TBL] [Abstract][Full Text] [Related]
15. The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance. Bennett J; Ielasi A; Torzewski J; de Hemptinne Q; Cerrato E; Lanocha M; Galli S; Sabaté M Cardiovasc Revasc Med; 2022 Jun; 39():106-113. PubMed ID: 34629285 [TBL] [Abstract][Full Text] [Related]
16. Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study. Toušek P; Lazarák T; Varvařovský I; Nováčková M; Neuberg M; Kočka V Cardiovasc Drugs Ther; 2022 Dec; 36(6):1129-1136. PubMed ID: 34505954 [TBL] [Abstract][Full Text] [Related]
17. Magmaris resorbable magnesium scaffold for the treatment of coronary heart disease: overview of its safety and efficacy. Bennett J; De Hemptinne Q; McCutcheon K Expert Rev Med Devices; 2019 Sep; 16(9):757-769. PubMed ID: 31345074 [No Abstract] [Full Text] [Related]
18. Magnesium versus poly-L-lactic acid bioresorbable scaffolds: in vivo optical coherence tomography comparison of mechanical performance. Abellás-Sequeiros RA; Ocaranza-Sanchez R; Galvaõ-Braga C; Marques J; Gonzalez-Juanatey C Arch Cardiol Mex; 2020; 90(1):8-15. PubMed ID: 31996867 [TBL] [Abstract][Full Text] [Related]
19. Magmaris very late in-scaffold restenosis: Has the "black boxes" nightmare come back? Bayón J; Santás-Álvarez M; Ocaranza-Sánchez R; González-Juanatey C Catheter Cardiovasc Interv; 2020 Aug; 96(2):E174-E176. PubMed ID: 31763757 [TBL] [Abstract][Full Text] [Related]
20. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study. Hideo-Kajita A; Garcia-Garcia HM; Haude M; Joner M; Koolen J; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Teik LS; Escaned J; Azizi V; Kuku KO; Ozaki Y; Dan K; Waksman R Cardiovasc Revasc Med; 2019 May; 20(5):392-398. PubMed ID: 31079817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]